Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2011-01-11
2011-01-11
Kolker, Dabiel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S194100, C530S403000, C435S235100
Reexamination Certificate
active
07867499
ABSTRACT:
The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the Aβ-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.
REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5508167 (1996-04-01), Roses et al.
patent: 5565548 (1996-10-01), Neurath et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5916818 (1999-06-01), Irsch et al.
patent: 5928647 (1999-07-01), Rock
patent: 5935821 (1999-08-01), Chatterjee et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6180771 (2001-01-01), Thomas et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6380364 (2002-04-01), Mueller et al.
patent: 6743427 (2004-06-01), Schenk
patent: 6827937 (2004-12-01), Murray
patent: 6919075 (2005-07-01), Solomon et al.
patent: 6932971 (2005-08-01), Bachmann et al.
patent: 6964769 (2005-11-01), Sebbel et al.
patent: 7115266 (2006-10-01), Bachmann
patent: 7128911 (2006-10-01), Bachmann et al.
patent: 7264810 (2007-09-01), Renner et al.
patent: 7279165 (2007-10-01), Bachmann et al.
patent: 7320793 (2008-01-01), Renner et al.
patent: 2002/0052311 (2002-05-01), Solomon et al.
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2003/0073655 (2003-04-01), Chain
patent: 2003/0157479 (2003-08-01), Bachmann et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 2003/0219459 (2003-11-01), Bachmann et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 2004/0136993 (2004-07-01), Schenk et al.
patent: 0 038 154 (1981-10-01), None
patent: 0 578 293 (1994-01-01), None
patent: 0 385 610 (1994-03-01), None
patent: 0 465 081 (1994-04-01), None
patent: 0 283 505 (1994-07-01), None
patent: 1 541 140 (2005-06-01), None
patent: 092022735 (1997-08-01), None
patent: 90/15878 (1990-12-01), None
patent: 94/15585 (1994-07-01), None
patent: 98/28624 (1998-07-01), None
patent: 98/40100 (1998-09-01), None
patent: 98/44955 (1998-10-01), None
patent: 99/27944 (1999-06-01), None
patent: 99/27949 (1999-06-01), None
patent: 99/28478 (1999-06-01), None
patent: 99/40934 (1999-08-01), None
patent: 99/57289 (1999-11-01), None
patent: 00/23955 (2000-04-01), None
patent: 00/32227 (2000-06-01), None
patent: 00/50461 (2000-08-01), None
patent: 01/18169 (2001-03-01), None
patent: 01/53457 (2001-07-01), None
patent: 01/53457 (2001-07-01), None
patent: 01/62284 (2001-08-01), None
patent: 01/85208 (2001-11-01), None
patent: 02/056905 (2002-07-01), None
patent: 02/056907 (2002-07-01), None
patent: 02/056907 (2002-07-01), None
patent: 03/024480 (2003-03-01), None
patent: 2004/016262 (2004-02-01), None
patent: 2004/016282 (2004-02-01), None
Adhin, M.R., et al., “Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification,” Virology 170(1):238-242, Academic Press, Inc. (1989).
Ansel, K.M., et al., “In Vivo-activated CD4 T Cells Upregulate CXC Chemokine Receptor 5 and Reprogram Their Response to Lymphoid Chemokines,” J. Exp. Med. 190(8):1123-1134, The Rockefeller University Press (1999).
Bachmann, M.F., and Zinkemagel, R.M., “The influence of virus structure on antibody responses and virus serotype formations,” Immunology Today 17 (12):553-558, Elsevier Science Ltd, (1996).
Bachmann, M.F., et al., “Dendritic cells process exogenous viral proteins and virus-like particles for class 1 presentation to CD8+ cytotoxic T lymphocytes,” Eur. J. Immunol. 26(11):2595-2600, VCH Verlagsgesellschaft mbH (1996).
Bachmann, M.F., et al., “TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-Independent T Helper Cell Activation,” J. Exp. Med. 189(7):1025-1031, The Rockefeller University Press (1999).
Bard, F. et al., “Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, ” Nat. Med. 6(8):916-919, Nature Publishing Company (2000).
Bass, S., and Yang, M., “Expressing cloned genes inEscherichia coli, ” in Protein Function: A Practical Approach, 2nd ed., Creighton, T.E., ed., IRL Press, Oxford, Great Britain, 175:29-55, (1997).
Bowie, J.U., et al., “Deciphering the message in protein sequences; tolerance to amino acid substitutions, ” Science 247(4948): 1306-1310, (1990).
Brown, W.L., et al., “RNA bacteriophage capsid-mediated drug delivery and epitope presentation,” Intervirology 45(4-6):371-380, S. Karger AG Basel (2002).
Cesareni, G., “Peptide display on filamentous phage capsids: A new powerful tool to study protein-ligand interaction,” FEBS Lett. 307(1):66-70, Elsevier Science Publishers B.V. (1992).
Chackerlan, B., et al., “Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles,” Proc Nat. Acad. Sci USA 96(5):2373-2378, (1999).
Crameri, R. and Suter, M., “Display of biologically active proteins on the surface of lilamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production,” Gene 137(1):69-75, Elsevier Science Publishers B.V. (1993).
de la Cruz, V.F., et al., “Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage,” J. Biol. Chem. 263:4318-4322, The American Society for Biochemistry and Molecular Biology, Inc. (1988).
Dodart, J.-C., et al., “Immunotherapy for Alzheimer's disease: will vaccination work?,” TRENDS in Molecular Medicine 9(3):85-87, (2003).
Donnelly, J.J., et al., “DNA Vaccines,” Annu. Rev. Immunol. 15:617-648, Annual Reviews, Inc. (1997).
Fehr, T., et al., “T cell-Independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles, ” Proc. Natl. Acad. Sci 95(16):9477-9481, (1998).
Fehr, T., et al., “Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies,” J. Exp Med. 185(10):1785-1792, The Rockefeller University Press (1997).
Frenkel, D., et al., “N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies,” J. Neuroimmunol. 88:85-90 (1998).
Frenkel, D., et al., “High affinity binding of monocional antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation,” J.Neuroimmunol. 95:136-142 (1999).
Frenel, D., et al., “Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration,” PNAS 97(21):11455-11459, (2000).
Frenkel, D., et al., “Generation of auto-antibodies towards Alzheimer's disease vaccination,” Vaccine 19(17-19):2615-2619, Elsevier Science, Ltd. (2001).
Frolov, I., et al., “Alphavirus-based expression vectors: strategies and applications,” Proc. Natl. Acad. Sci 93(21):11371-11377, (1996).
Games et al., “Alzheimer-type neuropathology in transgenic mice over-expressing V717F beta-amyloid precursor protein,” A letter in Nature, Feb. 9, 1995, 373:523-527.
Gilman, S., et al., “Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial,” Neurology 64(9):1553-1562, (2005).
Golmohammadi, R., et al., “The crystal structure of bacteriophage Q.beta. at 3.5.ANG, resolution,” Structure 4(5):543-554, Current Biology, Ltd. (1996).
Harris, S.J., et al., “Prediction of murine MHC class
Blättler Thomas
Graf Ana
Paganetti Paolo
Staufenbiel Matthias
Holmes Andrew K.
Kolker Dabiel E.
Novartis AG
LandOfFree
Methods of treating dementia by administering virus-like... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating dementia by administering virus-like..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating dementia by administering virus-like... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670723